ARTICLE
19 December 2025

Medical Devices Updates: Phase II Consultation On Medical Devices Regulations Amendments, Medical Device Licences Guidance And IMDRF Table Of Contents Guidance

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On November 17, 2025, Health Canada proposed Phase II amendments to the Medical Devices Regulations (MDR).
Canada Food, Drugs, Healthcare, Life Sciences
Nicole LaBerge’s articles from Smart & Biggar are most popular:
  • within Food, Drugs, Healthcare and Life Sciences topic(s)

Consultation on modernizing the medical device establishment licensing (MDEL) framework

On November 17, 2025, Health Canada proposed Phase II amendments to the Medical Devices Regulations (MDR). The first phase of amendments came into force on December 14, 2024 and relate to recalls, modernizing medical device establishment licence (MDEL) application requirements, and granting the Minister of Health authority to issue terms and conditions on an MDEL.

The proposed second phase of amendments for medical devices would:

  • remove the MDEL requirement for foreign distributors selling through Canadian importers with an MDEL,
  • clarify that MDEL holders must maintain documented procedures, and
  • require all MDEL applicants and licence holders to list suppliers of imported or sold devices.

The deadline for providing submissions on the proposed amendments is January 17, 2026. Feedback can be submitted through Canada Gazette, Part I: Regulatory Impact Analysis Statement and Regulatory Text.

Guidance on managing applications for medical device licences and adoption of International Medical Device Regulators Forum (IMDRF) table of contents

On November 21, 2025, Health Canada issued new guidance for managing applications for medical device licences, which will take effect on February 2, 2026. All applications in progress on or after that date, including reconsideration requests, will follow this guidance.

The guidance applies to the following types of medical device licences:

  • new and amendment Class II applications,
  • new and amendment (significant change) Class III applications,
  • new and amendment (significant change) Class IV applications,
  • minor change applications, and
  • new and amendment private label applications.

The guidance does not apply to applications submitted under Part 1.1 of the Regulations, which are for medical devices for an urgent public health need and have their own guidance document.

On November 25, 2025, Health Canada issued guidance for preparing table of contents based medical device applications, adopting the IMDRF format to encourage and support the global convergence of medical device applications. Health Canada anticipates that the use of the IMDRF table of contents will reduce costs and timelines, enabling faster access to medical devices in Canada.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

[View Source]
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More